Skip to main content
Premium Trial:

Request an Annual Quote

Mosaic Licenses DNA Bridge Technology to Affymax Technologies

Premium

BOSTON--Mosaic Technologies announced that it has granted a license and option relating to its patented Bridge amplification technology to Affymax Technolo gies, a wholly owned subsidiary of Glaxo Wellcome. The platform has broad applications in genomics-based drug development and pharmacogenomics, Mosaic said. Bridge amplification helps reduce time and expense by defining the genomic component and targeting the appropriate patient population, the company claimed.

Filed under

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.